Q2 2021 Thyrocare Technologies Ltd Earnings Call Transcript
I'm sorry sir, you are not very clear. You are not audible.
Am I now?
Yes, sir.
So I'll run out through some key highlights of quarterly results as well as quarterly financial results, which we have filed on 28th of October. And a brief presentation, which we have filed on the same day. Our stand-alone revenue for the current quarter stands at INR 148.54 crore, which is roughly 38% higher as compared to Y-o-Y same quarter last financial year.
We have seen a good revision in the current quarter. Our non COVID revenue has revised to the extent of 94% in the current quarter. Our current quarter core revenue stands about INR 48 crore. We have done about INR 2.76 lakh COVID RT-PCR investigation in the current quarter. As far as Nueclear is concerned, that is radiology arm of Thyrocare Group. They have achieved a total turnover of INR 4.71 crore in the current quarter. There, we could not see a good revival, but
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
